Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company's lead program is xB3-001, an xB3 peptide vector-trastuzumab fusion. It is developing xB3, a proprietary platform technology for the delivery of therapeutics and imaging agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders in the areas of high unmet medical needs, including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain metastases, glioblastomas, and neurodegenerative diseases. Bioasis Technologies Inc. has a collaborative research agreement with CQDM and Brain Canada to perform research on the delivery of therapeutic compounds across the BBB; and a strategic collaboration with BIOAGILYTIX for the development and validation of bioanalytical methods to support the xB3 TM-001 program, as well with WuXi Biologics (Hong Kong) Limited for the development and manufacturing of xB3-001 to treat cancer. The company was incorporated in 2006 and is headquartered in Guilford, Connecticut.
Industry, Sector and Symbol
Industry Drugs, proprietaries, & sundries
Sub-IndustryN/A
SectorMedical
Phone203-390-7395
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$460,000.00
Profitability
Miscellaneous
EmployeesN/A
OptionableNot Optionable
biOasis Technologies (OTCMKTS:BIOAF) Frequently Asked Questions
What is biOasis Technologies' stock symbol?
biOasis Technologies trades on the OTCMKTS under the ticker symbol "BIOAF."
When is biOasis Technologies' next earnings date?
Has biOasis Technologies been receiving favorable news coverage?
Media coverage about BIOAF stock has been trending somewhat positive on Monday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. biOasis Technologies earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term.
Who are some of biOasis Technologies' key competitors?
Who are biOasis Technologies' key executives?
biOasis Technologies' management team includes the folowing people:
- Dr. Deborah Ann Rathjen B.Sc. (Hons.), Q.C., Ph.D., M.A.I.C.D., FTSE, Exec. Chair (Age 61)
- Dr. Mark Day, Pres, CEO & Director
- Ms. Catherine London, Exec. VP and Head of Corp. Communications & Investor Relations
- Ms. Christine Antalik, Chief Financial Officer (Age 48)
- Mr. Kim Elton, Director of Marketing
How do I buy shares of biOasis Technologies?
Shares of BIOAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is biOasis Technologies' stock price today?
One share of BIOAF stock can currently be purchased for approximately $0.3683.
How big of a company is biOasis Technologies?
biOasis Technologies has a market capitalization of $21.58 million and generates $460,000.00 in revenue each year.
What is biOasis Technologies' official website?
How can I contact biOasis Technologies?
biOasis Technologies' mailing address is 14 Water Street, Guilford CT, 06437. The company can be reached via phone at 203-390-7395 or via email at [email protected]
MarketBeat Community Rating for biOasis Technologies (OTCMKTS BIOAF)
MarketBeat's community ratings are surveys of what our community members think about biOasis Technologies and other stocks. Vote "Outperform" if you believe BIOAF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOAF will underperform the S&P 500 over the long term. You may vote once every thirty days.
